Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15600586 | 1.00 | SIGMAR1 (0.34) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL15600585 | 1.00 | SIGMAR1 (0.34) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL15600620 | 1.00 | SIGMAR1 (0.34) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL15600584 | 1.00 | SIGMAR1 (0.34) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL15600618 | 1.00 | SIGMAR1 (0.34) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL15600612 | 1.00 | SIGMAR1 (0.34) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL14669650 | 0.90 | MAOA (0.35) | MAOAMAOB | |
| SCHEMBL14669811 | 0.90 | MAOA (0.35) | MAOAMAOB | |
| SCHEMBL14663875 | 0.90 | MAOA (0.35) | MAOAMAOB | |
| SCHEMBL14669496 | 0.90 | MAOA (0.35) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0865419-B1 | INDANE DIMER COMPOUNDS AND THEIR PHARMACEUTICAL USE | VENANTIUS LTD (IE) | 2003-08-06 | — | — | EP | claimed |
| US-6300376-B1 | FOR THERAPY TO ACHIEVE SMOOTH MUSCLE RELAXING ACTIVITY AND/OR MAST CELL STABILIZING ACTIVITY AND/OR ANTI-INFLAMMATORY ACTIVITY | VENANTIUS LIMITED (IR) | 2001-10-09 | — | — | US | claimed |
| EP-2864279-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASE | VENANTIUS LTD (IE) | 2016-11-02 | — | — | EP | disclosed |
| US-20150141523-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASE | VENANTIUS LIMITED (IE) | 2015-05-21 | — | — | US | disclosed |
| US-20150141523-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASE | VENANTIUS LIMITED (IE) | 2015-05-21 | — | — | US | disclosed |
| WO-2013174917-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASE | VENANTIUS LIMITED (IE) | 2013-11-28 | — | — | WO | disclosed |
| EP-0865419-B1 | INDANE DIMER COMPOUNDS AND THEIR PHARMACEUTICAL USE | VENANTIUS LTD (IE) | 2003-08-06 | — | — | EP | disclosed |
| US-6300376-B1 | FOR THERAPY TO ACHIEVE SMOOTH MUSCLE RELAXING ACTIVITY AND/OR MAST CELL STABILIZING ACTIVITY AND/OR ANTI-INFLAMMATORY ACTIVITY | VENANTIUS LIMITED (IR) | 2001-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141523-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASE | CD4, NFATC1, TPMT | SIGMAR1 4265/4885HTR2A 4838/4885HTR2C 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.